slc25a40 Antibody

What is SLC25A40 and what cellular functions does it perform?

SLC25A40 (solute carrier family 25 member 40) is a mitochondrial membrane protein with a reported length of 338 amino acid residues and a molecular mass of approximately 38.1 kDa in humans . It belongs to the Mitochondrial carrier (TC 2.A.29) protein family and functions as a probable mitochondrial transporter specifically required for glutathione import into mitochondria . Glutathione, an essential antioxidant exclusively produced in the cytosol, must be transported into various organelles including mitochondria to perform its critical functions . Within mitochondria, glutathione plays key roles in maintaining redox balance and supporting the activity and stability of iron-sulfur cluster-containing proteins . SLC25A40 also appears to support erythropoiesis (red blood cell production) through mechanisms that likely involve its glutathione transport capabilities . Gene orthologs of SLC25A40 have been identified across multiple species including mouse, rat, frog, zebrafish, chimpanzee, and chicken, suggesting evolutionary conservation of its important cellular functions .

How should researchers select an appropriate SLC25A40 antibody for specific research applications?

When selecting an SLC25A40 antibody for research, investigators should first identify their intended application, as different antibodies are optimized for specific techniques such as Western blotting, immunohistochemistry, immunofluorescence, or ELISA . Consider the target species, as available antibodies demonstrate varying reactivity profiles, with most commercial options being optimized for human SLC25A40 detection . Antibody format represents another critical selection parameter, with monoclonal antibodies offering higher specificity and reproducibility compared to polyclonal options which may provide superior sensitivity across multiple epitopes . The immunogen sequence should be evaluated to ensure the antibody targets relevant protein regions for your application—for example, Cell Signaling Technology's E9C7Y rabbit monoclonal antibody is produced against residues surrounding Lys330 of human SLC25A40 . Technical specifications including recommended dilutions, buffer formulations, and storage requirements should be carefully assessed to ensure optimal performance . Finally, validation data should be thoroughly examined, with preference given to antibodies supported by proper controls and cross-validation across multiple techniques as demonstrated in the manufacturer's specifications and literature citations .

What are the critical differences between monoclonal and polyclonal SLC25A40 antibodies in research applications?

Monoclonal and polyclonal SLC25A40 antibodies differ fundamentally in their production, specificity profiles, and optimal research applications. Monoclonal antibodies, such as Cell Signaling Technology's E9C7Y rabbit mAb, derive from single B-cell clones, ensuring consistent epitope recognition and superior lot-to-lot reproducibility . These antibodies target specific amino acid sequences, exemplified by the E9C7Y mAb which recognizes residues surrounding Lys330 of human SLC25A40 . In contrast, polyclonal options like Abcam's ab69075 result from multiple B-cell responses, recognizing various epitopes across the full-length SLC25A40 protein . Western blotting applications often reveal these differences, with monoclonals producing cleaner, more precise banding patterns at the expected 32-38 kDa range, while polyclonals may detect additional isoforms or modified variants . Monoclonal antibodies typically excel in applications requiring high specificity such as co-localization studies or when distinguishing between closely related protein family members, whereas polyclonals often demonstrate advantages in applications requiring robust signal amplification due to their multi-epitope binding capabilities . Selection should be guided by experimental priorities—specificity and reproducibility versus sensitivity and broad epitope recognition—with consideration of whether detection of potential variants or isoforms is desirable or potentially confounding to the research question .

What are the optimized protocols for SLC25A40 antibody use in Western blotting applications?

Optimized Western blotting protocols for SLC25A40 detection begin with effective sample preparation, requiring complete cell lysis using appropriate buffers that preserve mitochondrial proteins . The predicted molecular weight for SLC25A40 is approximately 38 kDa, but observed band sizes may vary between 32-38 kDa depending on the antibody and sample conditions . For protein separation, 10-12% SDS-PAGE gels are generally recommended, with proper transfer conditions (typically 100V for 60-90 minutes) to ensure complete transfer of mitochondrial membrane proteins . Primary antibody incubation should follow manufacturer recommendations, with Cell Signaling Technology's monoclonal antibody requiring a 1:1000 dilution , while Abcam's polyclonal antibody performs optimally at 1:500 dilution for Western blot applications . The specificity of detection can be validated through appropriate controls, as demonstrated in Abcam's validation data showing distinct banding patterns between SLC25A40-transfected and non-transfected 293T cell lysates . Secondary antibody selection should correspond to the host species of the primary antibody, such as anti-mouse IgG-HRP for mouse-derived antibodies or anti-rabbit IgG-HRP for rabbit-derived antibodies, typically used at dilutions between 1:2000-1:5000 . Signal detection optimization may require extended exposure times due to the relatively low endogenous expression levels of SLC25A40 in many cell types .

How should researchers optimize immunohistochemistry protocols for SLC25A40 detection in tissue sections?

Immunohistochemistry protocols for SLC25A40 require careful optimization, beginning with proper tissue fixation and antigen retrieval to ensure accessibility of mitochondrial epitopes. Sigma-Aldrich's anti-SLC25A40 antibody (HPA055197) has been extensively validated for immunohistochemistry and recommends dilutions between 1:50-1:200 . Antigen retrieval is typically performed using heat-induced epitope retrieval (HIER) in citrate buffer (pH 6.0) or EDTA buffer (pH 9.0), with heat treatment at 95-98°C for 15-20 minutes to expose mitochondrial membrane epitopes without disrupting tissue architecture . Blocking steps should utilize 5-10% normal serum from the same species as the secondary antibody for 1 hour at room temperature to minimize background staining that can obscure the specific mitochondrial pattern of SLC25A40 . Primary antibody incubation should occur overnight at 4°C to allow sufficient penetration and specific binding to mitochondrial structures within the tissue sections . Detection systems should be selected based on the desired sensitivity and signal amplification requirements, with polymer-based detection systems often providing superior results for mitochondrial proteins compared to traditional avidin-biotin complexes . Counterstaining should be kept minimal (light hematoxylin) to avoid obscuring the mitochondrial localization pattern of SLC25A40, and mounting media should be chosen to preserve fluorescence if immunofluorescence detection is employed .

What are the recommended sample preparation techniques for preserving SLC25A40 epitope integrity?

Effective sample preparation for SLC25A40 detection requires techniques that preserve mitochondrial membrane protein integrity. For cell culture samples, gentle lysis buffers containing 1% NP-40 or Triton X-100, supplemented with protease inhibitors and phosphatase inhibitors, help maintain protein conformation while effectively solubilizing membrane-bound SLC25A40 . Tissue samples benefit from rapid freezing in liquid nitrogen followed by homogenization in cold lysis buffer, minimizing proteolytic degradation of mitochondrial proteins . When processing samples for immunohistochemistry, fixation with 10% neutral buffered formalin for 24-48 hours strikes an optimal balance between structural preservation and epitope accessibility . For mitochondrial enrichment, subcellular fractionation using differential centrifugation can significantly enhance detection sensitivity, particularly in cells with lower SLC25A40 expression levels . Sample heating conditions require careful monitoring, as excessive heat can cause mitochondrial membrane protein aggregation; samples are typically heated at 70°C for 10 minutes rather than boiling . Protein quantification and equal loading are essential for comparative studies, with 25-50 μg of total protein typically loaded per lane for Western blot applications when detecting endogenous SLC25A40 . For immunofluorescence applications, fixation with 4% paraformaldehyde for 15 minutes followed by gentle permeabilization with 0.1-0.2% Triton X-100 for 10 minutes preserves mitochondrial morphology while allowing antibody access to SLC25A40 epitopes .

How can SLC25A40 antibodies be utilized to investigate mitochondrial glutathione transport mechanisms?

Investigation of SLC25A40's role in glutathione transport can be accomplished through multiple antibody-dependent approaches. Co-immunoprecipitation experiments using SLC25A40 antibodies can identify protein complexes involved in the glutathione transport machinery, revealing transient interaction partners that facilitate substrate movement across mitochondrial membranes . Immunofluorescence microscopy with SLC25A40 antibodies combined with glutathione-specific fluorescent probes enables visualization of spatial and temporal relationships between transporter localization and substrate distribution within cellular compartments . Proximity ligation assays utilizing SLC25A40 antibodies paired with antibodies against candidate interacting proteins can detect protein-protein interactions occurring within 40nm distance, providing evidence of functional transport complexes in situ . Cell fractionation followed by Western blotting with SLC25A40 antibodies quantifies transporter distribution between different mitochondrial subcompartments (outer membrane, intermembrane space, inner membrane, matrix), illuminating the precise localization relevant to glutathione transport . Time-course experiments analyzing SLC25A40 expression and localization under oxidative stress conditions can reveal regulatory mechanisms governing transporter activity in response to changing cellular redox states . Knockdown/overexpression validation approaches, where SLC25A40 antibodies confirm successful protein manipulation, combined with glutathione transport assays, provide direct evidence of the transporter's functional role in glutathione movement across mitochondrial membranes .

What techniques can researchers employ to study SLC25A40's role in cancer drug resistance mechanisms?

Investigation of SLC25A40's involvement in cancer drug resistance requires multifaceted technical approaches centered around specialized antibody applications. Single-cell clonal expansion with subsequent antibody-based validation can establish isogenic cell lines that differ only in SLC25A40 expression status, creating powerful experimental models for comparative drug resistance studies as demonstrated in high-grade serous ovarian cancer research . Immunohistochemical analysis of patient-derived xenografts using calibrated antibody protocols enables correlation between SLC25A40 expression patterns and treatment response metrics, providing clinically relevant insights into resistance mechanisms . Flow cytometry applications utilizing permeabilization protocols optimized for mitochondrial proteins allow quantification of SLC25A40 levels in heterogeneous tumor cell populations and correlation with drug efflux activities or apoptotic resistance . Chromatin immunoprecipitation followed by sequencing (ChIP-seq) using antibodies against transcription factors regulating SLC25A40 expression can identify regulatory networks governing its upregulation in resistant cancer cells . Particular attention should be paid to SLC25A40-ABCB1 fusion detection through specialized antibody panels that can distinguish between wild-type proteins and fusion products through differential epitope recognition patterns . Combination of SLC25A40 antibody-based protein detection with metabolomic profiling of glutathione pathway components provides mechanistic insights into how altered mitochondrial redox homeostasis contributes to drug detoxification and resistance phenotypes . High-throughput FDA drug screening approaches, complemented by immunoblotting validation of SLC25A40 status, can identify novel therapeutic compounds effective against resistant cell populations with altered SLC25A40 expression or fusion status .

How can researchers distinguish between wild-type SLC25A40 and SLC25A40-ABCB1 fusion proteins in experimental systems?

Distinguishing between wild-type SLC25A40 and SLC25A40-ABCB1 fusion proteins requires strategic antibody selection and specialized detection approaches. Epitope-specific antibody panels provide the foundation for differential detection, employing antibodies targeting the N-terminal region of SLC25A40 (present in both wild-type and fusion proteins) alongside antibodies recognizing the C-terminal region (absent in fusion proteins following the ~250 kb deletion described in fusion-positive cancer cells) . Western blot analysis using these epitope-specific antibodies reveals diagnostic banding patterns—wild-type SLC25A40 appearing at approximately 38 kDa while fusion proteins display altered molecular weights depending on the specific fusion breakpoints . Immunofluorescence co-localization studies utilizing dual-labeled antibodies against SLC25A40 (N-terminal) and ABCB1 markers can visually distinguish normal mitochondrial localization from aberrant localization patterns characteristic of fusion proteins . PCR-validated cellular models provide essential controls for antibody validation, with single-cell SLC25A40-ABCB1 fusion-negative and positive clones serving as reference standards for optimizing detection protocols . Variant allele frequency (VAF) determined through genetic analysis helps researchers interpret heterogeneous antibody staining patterns, with the understanding that a VAF of 0.2 suggests approximately 40% of cellular populations harbor heterozygous deletions leading to fusion transcripts . RNA-sequencing data correlated with protein detection helps confirm the relationship between transcriptional fusion events and the resulting chimeric proteins detected by antibody-based methods . For quantitative applications, carefully calibrated standard curves using recombinant proteins representing both wild-type SLC25A40 and fusion constructs enable precise measurement of relative protein abundances in experimental samples .

What are the common technical challenges in SLC25A40 antibody applications and their solutions?

Researchers frequently encounter several technical challenges when working with SLC25A40 antibodies, each requiring specific troubleshooting approaches. Non-specific background in Western blotting commonly occurs with SLC25A40 detection, requiring optimized blocking conditions (5% BSA often performs better than milk-based blockers) and increased washing stringency with 0.1% Tween-20 in TBS buffer . Variable detection sensitivity between experimental replicates can be addressed through careful antibody aliquoting to avoid freeze-thaw cycles, maintaining consistent incubation temperatures (4°C overnight typically yields more reproducible results than room temperature incubations), and utilizing enhanced chemiluminescence detection systems with extended exposure times . Mitochondrial protein extraction efficiency significantly impacts SLC25A40 detection, necessitating specialized extraction buffers containing 1-2% digitonin or 0.5-1% DDM (n-dodecyl β-D-maltoside) to effectively solubilize mitochondrial membrane proteins without denaturing critical epitopes . Multiple banding patterns observed with some antibodies require careful validation through positive controls (SLC25A40-transfected cell lysates as demonstrated with Abcam's antibody) and negative controls (knockout or siRNA-treated samples) to distinguish specific from non-specific signals . Antibody cross-reactivity with related mitochondrial carrier family proteins can be evaluated through peptide competition assays using immunizing peptides or recombinant protein fragments corresponding to the specific SLC25A40 epitope sequence, such as the "FVYSNGLMDHLCVCEEGGNKLWYKKPGNFQGTLDAFFKIIRNEGIK" sequence used for the Sigma-Aldrich antibody . Epitope masking in fixed tissues often necessitates optimized antigen retrieval methods, with comparative testing of citrate buffer (pH 6.0) versus EDTA buffer (pH 9.0) at varying incubation times to maximize signal recovery .

How should researchers validate the specificity of SLC25A40 antibodies for their particular experimental systems?

Comprehensive validation of SLC25A40 antibodies requires a multi-tiered approach to ensure reliable experimental outcomes across different systems. Genetic knockdown/knockout validation represents the gold standard, where siRNA/shRNA-mediated SLC25A40 depletion or CRISPR/Cas9 knockout should result in corresponding signal reduction or elimination when probed with the antibody under investigation . Recombinant protein overexpression systems provide complementary validation, as demonstrated in Abcam's approach using SLC25A40-transfected 293T cells compared to non-transfected controls, where specific antibodies should show enhanced signal intensity proportional to expression levels . Multiple antibody concordance testing employs different antibodies targeting distinct SLC25A40 epitopes (such as comparing N-terminal versus C-terminal targeting antibodies) to confirm consistent detection patterns across independent reagents . Peptide competition assays using the immunizing peptide sequence should result in signal elimination when the antibody is pre-incubated with excess peptide, confirming epitope-specific binding . Cross-species reactivity assessment based on epitope sequence conservation can provide additional validation when human SLC25A40 antibodies are applied to model organisms, though researchers should note that not all commercially available antibodies have been validated across orthologs despite the reported conservation in mouse, rat, frog, zebrafish, chimpanzee and chicken species . Application-specific validations are essential, as antibodies performing well in Western blotting may not maintain specificity in immunohistochemistry or immunofluorescence applications, requiring independent validation for each experimental methodology . Mass spectrometry confirmation of immunoprecipitated proteins provides definitive validation by identifying the presence of SLC25A40-specific peptides in antibody-captured protein complexes .

What positive and negative control samples are essential when using SLC25A40 antibodies?

Implementing appropriate control samples is critical for accurate interpretation of SLC25A40 antibody results across experimental platforms. Positive expression controls should include human cell lines with confirmed SLC25A40 expression, with demonstrated utility in K562 leukemia cells where SLC25A40 has been implicated in drug resistance mechanisms . Genetically modified expression systems, such as the SLC25A40-transfected 293T cells utilized in Abcam's validation studies, provide robust positive controls with enhanced signal intensity compared to endogenous expression levels . Tissue microarrays representing multiple normal human tissues can serve as anatomical expression references, reflecting the tissue-specific expression patterns documented through the Human Protein Atlas project referenced in Sigma-Aldrich's antibody characterization . For negative controls, siRNA/shRNA-mediated knockdown of SLC25A40 in relevant cell lines provides essential validation of antibody specificity when signal reduction proportional to knockdown efficiency is observed . Peptide competition controls, where the antibody is pre-incubated with excess immunizing peptide prior to application, should demonstrate substantially reduced or eliminated staining when compared to non-competed antibody applications . For immunohistochemistry applications, isotype-matched control antibodies lacking specific target recognition should be applied to serial sections using identical staining protocols to identify potential non-specific background . When studying SLC25A40-ABCB1 fusion proteins, control samples should include both fusion-negative and fusion-positive cell clones, as employed in studies of high-grade serous ovarian cancer, to validate differential detection patterns . Subcellular fractionation controls comparing mitochondria-enriched versus cytosolic fractions should demonstrate appropriate compartmentalization of SLC25A40 signal to mitochondrial fractions, confirming both antibody specificity and expected localization patterns .

How should researchers interpret varying band patterns in Western blots using SLC25A40 antibodies?

Interpretation of SLC25A40 Western blot banding patterns requires careful consideration of multiple biological and technical factors. The canonical human SLC25A40 protein has a predicted molecular weight of 38.1 kDa, but experimental observations reveal bands ranging from 32-38 kDa across different antibodies and cell types . This variation may reflect post-translational modifications, proteolytic processing, or isoform expression rather than non-specific binding . Multiple bands near the expected molecular weight should be evaluated in the context of positive and negative controls—Abcam's validation data shows a specific band at 35 kDa in SLC25A40-transfected 293T cells that is absent in non-transfected controls, suggesting this represents the specific target despite the slight molecular weight deviation . Cell Signaling Technology's monoclonal antibody detects a predominant band at 32 kDa, indicating potential differences in epitope accessibility, protein processing, or technical factors affecting apparent molecular weight . When investigating SLC25A40-ABCB1 fusion proteins in cancer cell models, researchers should be prepared to observe additional bands representing fusion products, with molecular weights determined by the specific fusion breakpoints . The presence of higher molecular weight bands (>50 kDa) may indicate protein complexes resistant to complete denaturation, post-translational modifications such as ubiquitination, or oligomerization—phenomena reported for other mitochondrial carrier family proteins . Lower molecular weight bands (<30 kDa) might represent degradation products, proteolytic processing, or alternative translation initiation sites, requiring validation through inhibitor studies or expression of truncated constructs . Statistical analysis of band intensity should employ normalization to both loading controls and positive expression controls to account for technical variation across experiments .

What approaches can differentiate between SLC25A40's role in glutathione transport versus other potential functions?

Distinguishing SLC25A40's glutathione transport function from other potential roles requires methodologically rigorous experimental designs. Functional transport assays using isolated mitochondria from cells with normal versus altered SLC25A40 expression provide direct evidence of glutathione transport capacity, with fluorescently labeled glutathione analogs enabling real-time monitoring of substrate movement across membranes . Correlative metabolomics approaches measuring mitochondrial and cytosolic glutathione pools in SLC25A40-manipulated cells can establish quantitative relationships between transporter expression levels and compartment-specific glutathione concentrations . Structure-function analysis utilizing antibodies against wild-type SLC25A40 versus site-directed mutants affecting key functional domains can dissect transport-specific versus potential regulatory functions, similar to approaches used with other mitochondrial carrier family proteins . Interactome mapping through co-immunoprecipitation followed by mass spectrometry identifies SLC25A40-associated proteins, potentially distinguishing between those involved in glutathione transport versus alternative functions such as protein stability regulation or signal transduction . Redox-sensitivity studies examining how oxidative stress alters SLC25A40 expression, localization, and post-translational modifications can reveal functional adaptations specific to glutathione transport versus general stress responses . Comparison with other known glutathione transporters through parallel knockdown/overexpression studies allows assessment of functional redundancy versus unique contributions of SLC25A40 to glutathione homeostasis . Disease model correlations, particularly focusing on conditions with altered glutathione metabolism versus those affecting other mitochondrial functions, help contextualize the relative importance of different SLC25A40 functional roles in pathophysiological settings .